GetTopicDetailResponse(id=1f611289363, topicName=NMPA授予優(yōu)先審查, introduction=NMPA授予優(yōu)先審查, content=null, image=null, comments=1, allHits=899, url=https://h5.medsci.cn/topic?id=12893, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102679, tagList=[TagDto(tagId=102679, tagName=NMPA授予優(yōu)先審查)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1488603, encodeId=589c14886032f, content=<a href='/topic/show?id=1f611289363' target=_blank style='color:#2F92EE;'>#NMPA授予優(yōu)先審查#</a>, objectTitle=再鼎醫(yī)藥的PARP抑制劑Niraparib用于卵巢癌維持治療，獲得NMPA授予優(yōu)先審查, objectType=article, longId=192482, objectId=1c3c1924827f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c3c1924827f, replyNumber=0, likeNumber=104, createdTime=2020-04-20, rootId=0, userName=lmm400, userId=3a698448997, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c3c1924827f, moduleTitle=再鼎醫(yī)藥的PARP抑制劑Niraparib用于卵巢癌維持治療，獲得NMPA授予優(yōu)先審查, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1c3c1924827f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
